Get the Stockscreener App
68.24
0.47%
-0.32
After Hours:
68.24
Arcellx Inc stock is traded at $68.24, with a volume of 505.94K.
It is down -0.47% in the last 24 hours and down -9.03% over the past month.
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
See More
Previous Close:
$68.56
Open:
$68.56
24h Volume:
505.94K
Relative Volume:
0.81
Market Cap:
$3.69B
Revenue:
$155.82M
Net Income/Loss:
$-40.42M
P/E Ratio:
-96.11
EPS:
-0.71
Net Cash Flow:
$3.58M
1W Performance:
+0.98%
1M Performance:
-9.03%
6M Performance:
+31.92%
1Y Performance:
+3.57%
1-Day Range:
$67.04
$69.43
1-Week Range:
$63.38
$70.24
52-Week Range:
$47.88
$107.37
Arcellx Inc Stock (ACLX) Company Profile
Name
Arcellx Inc
Sector
Industry
Phone
240-327-0603
Address
800 BRIDGE PARKWAY, REDWOOD CITY
Compare ACLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
68.24 | 3.69B | 155.82M | -40.42M | 3.58M | -0.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Sep-03-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Mar-07-24 | Initiated | Morgan Stanley | Overweight |
| Jan-04-24 | Reiterated | Needham | Buy |
| Dec-19-23 | Initiated | Scotiabank | Sector Outperform |
| Oct-30-23 | Initiated | TD Cowen | Outperform |
| Oct-17-23 | Initiated | UBS | Buy |
| May-18-23 | Initiated | Truist | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
| Mar-14-23 | Initiated | Stifel | Buy |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-13-22 | Resumed | BofA Securities | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-27-22 | Initiated | Needham | Buy |
| Jul-20-22 | Initiated | Canaccord Genuity | Buy |
| Mar-01-22 | Initiated | BofA Securities | Buy |
| Mar-01-22 | Initiated | SVB Leerink | Outperform |
View All
Arcellx Inc Stock (ACLX) Latest News
Kavita Patel Sells 1,500 Shares of Arcellx, Inc. (NASDAQ:ACLX) Stock - Armenian Reporter
Arcellx, Inc. (NASDAQ:ACLX) Director Sells $96,855.00 in Stock - MarketBeat
Taking a Closer Look At Arcellx Inc (ACLX) Following Its Recent Trade - Knox Daily
Financial Review: Arcellx (NASDAQ:ACLX) versus C4 Therapeutics (NASDAQ:CCCC) - Defense World
arcellx director kavita patel sells $96,854 in stock - MSN
arcellx director kavita patel sells $96,854 in stock By Investing.com - Investing.com Australia
(ACLX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Arcellx (NASDAQ:ACLX) Stock Price Down 5.4%Should You Sell? - MarketBeat
Brokerages Set Arcellx, Inc. (NASDAQ:ACLX) PT at $105.93 - MarketBeat
Moody Aldrich Partners LLC Sells 16,122 Shares of Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Short Interest Update - MarketBeat
Analysts Set Arcellx, Inc. (NASDAQ:ACLX) PT at $105.93 - Defense World
Vanguard Group Inc's Strategic Acquisition of Arcellx Inc Shares - GuruFocus.com
Stifel maintains Buy on Arcellx shares, target at $122 - MSN
Stifel maintains Buy on Arcellx shares, target at $122 By Investing.com - Investing.com Canada
(ACLX) On The My Stocks Page - Stock Traders Daily
Cantor Fitzgerald Estimates Arcellx FY2025 Earnings - Defense World
Brokers Issue Forecasts for Arcellx FY2025 Earnings - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Sees Significant Growth in Short Interest - Defense World
Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Expands By 6.6% - MarketBeat
Arcellx, Inc.: Trying To Build A Better Myeloma Cell Therapy - Seeking Alpha
Arcellx director Kavita Patel sells $98,801 in stock By Investing.com - Investing.com Australia
Arcellx, Inc. (NASDAQ:ACLX) Director Kavita Patel Sells 1,500 Shares - MarketBeat
Arcellx director Kavita Patel sells $98,801 in stock - Investing.com India
(ACLX)Analyzing Arcellx's Short Interest - Benzinga
Oversold Conditions For Arcellx (ACLX) - Nasdaq
Arcellx, Inc. (NASDAQ:ACLX) Insider Sells $261,820.57 in Stock - MarketBeat
Arcellx's chief medical officer sells shares worth $581,315 By Investing.com - Investing.com Australia
arcellx CEO Elghandour sells stock worth $2.26 million By Investing.com - Investing.com Nigeria
Arcellx CFO Michelle Gilson sells shares worth $700,959 By Investing.com - Investing.com Australia
arcellx CEO Elghandour sells stock worth $2.26 million - Investing.com
Arcellx CFO Michelle Gilson sells shares worth $700,959 - Investing.com India
Arcellx Breaks Below 200-Day Moving AverageNotable for ACLX - Nasdaq
Arcellx's chief medical officer sells shares worth $581,315 - Investing.com
JPMorgan Chase & Co. Sells 38,336 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx, Inc. (NASDAQ:ACLX) Receives $105.93 Consensus Price Target from Brokerages - Defense World
Arcellx's chief medical officer sells shares worth $498,795 By Investing.com - Investing.com Australia
Arcellx CFO Michelle Gilson sells $831,378 in stock By Investing.com - Investing.com Nigeria
Principal Financial Group Inc. Has $336,000 Stock Position in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Arcellx CEO Rami Elghandour sells shares worth $2.24 million By Investing.com - Investing.com Australia
Arcellx Inc Stock (ACLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):